Delivery Order SPE2DB20D7066-SPE2DB25FC4CG
- Not listed
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,024.04 firm fixed-price contract is for the supply of Linzess 290 MCG capsules, and has a period of performance through February 19, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,017.18 firm fixed-price delivery order is for the supply of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product. The contract has an ultimate completion date of March 3, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,451.78 fixed-price delivery order is for the supply of LINZESS 290 MCG capsules to support military healthcare programs. The contract has an ultimate completion date of March 8, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,453.09 firm fixed-price contract is for the delivery of LINZESS 72 MCG capsules. The contract has an ultimate completion date of December 12, 2023. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $3,143.06 delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 30-count capsules of the medication Linzess 145 MCG. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. The IDC allows DLA to efficiently procure a wide range of...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of the prescription medication LINZESS 72 MCG CAPSULE UU 30S. The firm-fixed-price contract has a ceiling value of $7,590.99 and a completion date of July 2, 2025. It is not a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distributor. The $2,712.96 contract is for the supply of LINZESS 145MCG 30S, a brand name prescription medication. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA to...
- This is a delivery order federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $1,715.99 firm-fixed-price contract is for the delivery of LINZESS 72 MCG CAPSULE UU 30S pharmaceutical products. The contract has a completion date of May 23, 2025 and is not set aside for any socioeconomic program. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp for the supply of LINZESS 145 MCG capsules. The contract has a firm fixed price of $4,196.85 and a period of performance through August 15, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with DLA Troop Support Medical, valued at up to $999,999,999, for delivering a wide range of pharmaceutical and medical supplies to support military...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 290 MCG CAPSULE medication, with a ceiling value of $2,214.08 and a completion date of July 3, 2025. The contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB25FC4CGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Linzess 72 mg capsules in a 30-count unit pack, with a contract ceiling value of $1,495.59 and an ultimate completion date of July 21, 2025. This firm fixed price delivery order represents a non-competitive award and is classified as a child contract under AmerisourceBergen's larger federal contracting framework. The performance location is the company's corporate office in Conshohocken, Pennsylvania, which serves as a critical hub for the firm's federal medical procurement operations. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications and medical commodities to support military healthcare programs and federal medical supply chains. The Linzess order reflects the company's role in providing specialized pharmaceutical products across multiple therapeutic domains to support Defense Health Agency and related federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 7/18/25 |